Ataluren
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Muscular Dystrophy, Duchenne
Conditions
Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
Trial Timeline
Mar 20, 2014 → Jun 12, 2018
NCT ID
NCT02090959About Ataluren
Ataluren is a phase 3 stage product being developed by PTC Therapeutics for Muscular Dystrophy, Duchenne. The current trial status is terminated. This product is registered under clinical trial identifier NCT02090959. Target conditions include Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic.
What happened to similar drugs?
14 of 20 similar drugs in Muscular Dystrophy, Duchenne were approved
Approved (14) Terminated (2) Active (5)
Hype Score Breakdown
Clinical
17
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04336826 | Phase 2 | Completed |
| NCT03796637 | Phase 2 | Completed |
| NCT04117880 | Phase 2 | Withdrawn |
| NCT03648827 | Phase 2 | Completed |
| NCT02819557 | Phase 2 | Completed |
| NCT02456103 | Phase 3 | Terminated |
| NCT02107859 | Phase 3 | Terminated |
| NCT02090959 | Phase 3 | Terminated |
| NCT01557400 | Phase 3 | Completed |
| NCT01247207 | Phase 3 | Completed |
| NCT01140451 | Phase 3 | Completed |
| NCT00458341 | Phase 2 | Completed |
| NCT00237380 | Phase 2 | Completed |
Competing Products
20 competing products in Muscular Dystrophy, Duchenne